Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Aug;5(4):274-9.
doi: 10.1007/s11934-004-0050-6.

The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data

Affiliations
Review

The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data

Jaspreet S Sandhu et al. Curr Urol Rep. 2004 Aug.

Abstract

Medical treatment for the symptoms of benign prostatic hyperplasia (BPH) consists of a blockers and 5-alpha-reductase inhibitors. Data suggest that 5-alpha-reductase inhibitors can prevent progression of BPH and reduce the risk of BPH-related surgery, especially in men with large-volume prostates. Results from the largest randomized, prospective, placebo-controlled trial, the Medical Therapy of Prostatic Symptoms trial, have been presented. These results support the notion of using 5-alpha-reductase inhibitors for the prevention of BPH progression and BPH-related surgery. Furthermore, long-term 5-alpha-reductase inhibitor monotherapy, although slow in onset, is a viable therapy for symptom relief in men with mild to moderate symptoms.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Urol. 2002 Jun;167(6):2489-91 - PubMed
    1. Br J Urol. 1995 Jul;76 Suppl 1:5-10 - PubMed
    1. Eur Urol. 1992;22(4):271-7 - PubMed
    1. Urology. 2003 Feb;61(2):354-8 - PubMed
    1. Urology. 2001 Jun;57(6):1073-7 - PubMed

MeSH terms

LinkOut - more resources